FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk

Dow Jones

Yesterday

By Nicholas G. Miller

The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes.

The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events.

European regulators granted Rybelsus similar approval earlier this year.

The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes.

The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year.

Write to Nicholas G. Miller at nicholas.miller@wsj.com

(END) Dow Jones Newswires

October 17, 2025 17:55 ET (21:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2576062232"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576062232\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576062232?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-18 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576062232","market":"fut","top_or_hot":-1,"title":"FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The Food and Drug Administration approved <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events. \n</p>\n<p>\n  European regulators granted Rybelsus similar approval earlier this year. \n</p>\n<p>\n  The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 17, 2025 17:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-18 05:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The Food and Drug Administration approved <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events. \n</p>\n<p>\n  European regulators granted Rybelsus similar approval earlier this year. \n</p>\n<p>\n  The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 17, 2025 17:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576062232","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576062232","pubTimestamp":1760738100,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes.The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events.European regulators granted Rybelsus similar approval earlier this year.The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes.The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"FDA批准诺和诺德的Rybelsus糖尿病药丸可降低心脏风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. \n\n\n  The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events. \n\n\n  European regulators granted Rybelsus similar approval earlier this year. \n\n\n  The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes. \n\n\n  The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 17, 2025 17:55 ET (21:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}